*Nabriva治疗公司-公司计划向美国食品和药物管理局提交一份新的药物申请
*Nabriva治疗公司PLC-LEFAMULIN满足了FDA和EMA的所有主要终点...查看全文
淘沙见金2018-05-22 07:09
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ Liver tox. 1 case of >10x ALT as well as AST.Worse liver tox numbers for lefamulin at 5x and 10x, but none met Hy's law. 10X diarrhea and 1 case of cdiff. 股价大跌是因为药物的安全表现有瑕疵。这就是没有公司愿意做抗生素...查看全文
美股医药Z博士2017-12-21 02:40
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 今年9月,公司的LEAP1 3期临床试验取得了很好的结果,股价一度飙升至14。但因为增发原因,股价在8块左右徘徊了一阵,在上周跌破5块。公司前不久宣布LEAP2 III期临床试验已经结束,LEAP2与LEAP1非常相似,只是剂型从静脉注射换成口服,虽然小药...查看全文
淘沙见金2017-09-19 12:53
Nabriva Therapeutics( $Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ )是一家研究新型抗生素的生物医药公司,于今日宣布第一项社区获得性细菌性肺炎(CABP)试验满足了非劣性的要求,股票曾一度大涨,后又回落到$9左右。Nabriva Therapeutics在盘后宣布公司即将增发价值$80M +$12M overall...查看全文
淘沙见金2017-09-18 20:17
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ Thinly traded micro cap Nabriva Therapeutics (NASDAQ:NBRV) is up 92% premarket on light volume in response to its announcement of positive top-line results from a Phase 3 clinical trial, LEAP 1, evaluating intravenous to or...查看全文
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 1.01, 1.02, 2.01, 5.02, 8.01, and 9.01 Accession Number: 0001104659-23-085605 Act: 34 Size: 853 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, item 3.01 Accession Number: 0001104659-23-083250 Act: 34 Size: 199 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001104659-23-079722 Size: 2 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001104659-23-079724 Size: 3 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001104659-23-079156 Act: 34 Size: 507 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, item 3.01 Accession Number: 0001104659-23-067071 Act: 34 Size: 173 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-23-010302 Act: 34 Size: 5 MB 网页链接
$Nabriva Therapeutics(NBRV)$ NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB Accession Number: 0001104659-23-060936 Act: 34 Size: 23 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001558370-23-006062 Act: 34 Size: 11 MB 网页链接
$Nabriva Therapeutics(NBRV)$ NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 Accession Number: 0001104659-23-040216 Act: 34 Size: 24 KB 网页链接